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Abstract
Background The absence of neurological symptoms and
signs is traditionally considered mandatory for a diagnosis
of type 1 Gaucher disease (GD1), but in recent years many
reports have emerged on neurological manifestations in
GD1 patients. Nevertheless, it has been unclear whether
cognitive deficits are part of the disease as well.
Methods Cognitive function was assessed in a large cohort
of GD1 patients with the use of the CDR system, a set of
computerised cognitive tests. Testing was performed at
baseline and every 6 months thereafter during a two-year
study period.
Results Our patient cohort (84 patients, median age 40 years,
median time from diagnosis 15 years) showed mild deficits
relative to healthy age-matched subjects on the composite
scores: power of attention (Z-score (mean ± SD) -0.9±1.37)
and speed of memory (Z-score (mean ± SD) -1.39±1.49).
No decline in cognitive function was seen during the two-
year period. Age correlated with the composite scores var-
iability of attention and quality of working memory. More-
over, severely affected patients (Zimran severity score (SSI)
≥ 15) scored more poorly compared to mildly affected
patients (SSI ≤ 5) on the composite measure power of
attention, reflecting the ability to concentrate.
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Conclusions GD1 patients exhibit mild deficits in power of
attention and speed of memory, reflecting a decreased ability
to focus attention and process information, together with a
slowing in the speed of retrieval of items from memory. The
clinical relevance of these findings is uncertain.
Background
Gaucher disease is one of the most common lysosomal
storage diseases with an estimated prevalence of 1 in
40,000 to 50,000 live births (Grabowski 2008). The disease
is caused by mutations in the glucocerebrosidase (GBA)
gene resulting in a decreased activity of the enzyme and
subsequent accumulation of glucocerebrosides in macro-
phages throughout the body. The absence of nervous system
involvement is used as a criterion in the classic definition of
type 1 Gaucher disease (GD1). However, peripheral as well
as central nervous system disease has been described in type
1 Gaucher disease. We recently reported an increased prev-
alence and incidence of polyneuropathy in GD1 patients
compared with the general population (Biegstraaten et al
2010). In addition, GD1 and GBA mutations have been
associated with Parkinson disease (PD) and Dementia with
Lewy Bodies (DLB) (Goker-Alpan et al 2006; Sidransky et
al 2009). Moreover, an autopsy study on 14 Gaucher brains
showed neuropathological changes not only in type 2 and 3
patients but also in patients with type 1 disease. Selective
vulnerability of the hippocampal CA2-4 regions, cerebral
cortical layers 3 and 5 and calcarine cortex layer 4b with
normal adjacent regions have been found in all three types
of Gaucher disease, although there were qualitative and
quantitative differences between the three types; neurode-
generation predominated in type 2 and 3 disease, whereas
astrogliosis was the only manifestation in type 1 patients
(Wong et al 2004).
Following the observation of a case of dementia during
a clinical trial with the substrate reduction therapy miglu-
stat (ZavescaTM, Actelion Pharmaceuticals Ltd, Allschwil,
Switzerland) (Elstein et al 2005), the question arose
whether the cognitive decline in this patient was miglustat-
related, a coincidence or part of GD1. As part of a post-
marketing surveillance commitment to the European
Medicines Agency (EMA) in relation to the registration
of miglustat, we conducted a multi-centre study, under
the auspices of the European Working Group on Gaucher
Disease, to investigate comorbidities in GD1, with a
special focus on peripheral neuropathy; the main findings
have been reported elsewhere (Biegstraaten et al 2010).
Besides, the cognitive profile of GD1 patients was inves-
tigated. In this paper we present data on the cognitive
profile of GD1 patients and the changes over a two-year
study period.
Methods
Study design
This 2-year prospective, longitudinal, observational cohort
study was conducted in eight centres across seven countries
in Europe.
Patients
Eligible adult patients diagnosed with GD1 by glucocere-
brosidase assay or molecular genetic analysis, attending
routine clinical visits, and receiving either no treatment or
enzyme replacement therapy (ERT) were enrolled between 3
May 2005 and 28 December 2006. Those with a history of
manifestations or mutations associated with type 3 disease
were excluded. Patients were also excluded if they were
undergoing or had undergone treatment with miglustat or
an investigational agent, or if they had neurological or
psychiatric conditions that could influence cognitive perfor-
mance. Finally, patients with a yet undefined mutation were
excluded from the analyses.
Patients who attended at least one post baseline visit were
included in the analyses. All patients provided written,
informed consent before participation. The study protocol
was approved by independent local ethics committees, and
was conducted in accordance with the Declaration of
Helsinki, 1964, and subsequent revisions.
Assessments
Disease severity was assessed at baseline using the Zimran
severity score index (SSI) (Zimran et al 1992). On study
entry (baseline), and every six months thereafter, patients
underwent cognitive function testing with the CDR system,
a validated computerised cognitive assessment system,
(Simpson et al 1991). The 30-minute test battery was ad-
ministered in a quiet room, one-to-one, by trained admin-
istrators using standardised task instructions in the patient’s
native language. The CDR system has been validated in the
various languages required for the present study. Patients
had two training sessions on the tests during the 14 days
prior to baseline. During each test session, the following
tests were administered: simple reaction time, digit vigi-
lance, choice reaction time, spatial working memory, nu-
meric working memory, delayed word recognition, delayed
picture recognition and morse tapping (see (Wesnes et al
2000) for full task descriptions).
In addition to the analysis of individual task measures, six
predefined, validated CDR composite scores were used: pow-
er of attention, continuity of attention, quality of episodic
memory, quality of working memory, speed of memory and
variability of attention (Table 1) (Wesnes et al 2000).
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Analysis
To compare the cognitive profile of the GD1 population with
the general population, age-matched scores were identified
from the normative database of the CDR system in various
age-bands (see Table 2). The normative database comprises
data from over 5000 healthy individuals aged 18 to 87 years,
whowere free of any psychiatric or major medical condition at
the time of testing (Wesnes 2006). The nationalities of the
individuals were American, Belgian, Danish, Dutch, English,
French, German, Swedish and Swiss, and around 2% of the
individuals were Afro-Carribean or Asian, the rest being
Caucasian.
Using the normative data, the patients’ data were Z-
transformed and mean ± SD GD1 population Z-scores were
calculated by age-group. Z-scores were transformed so that
higher scores always indicate better performance. Furthermore,
95% confidence intervals (95%CIs) were calculated. In addi-
tion, repeated measures analysis of covariance (ANCOVA) was
performed on the change from baseline data over the follow-up
assessments (6, 12, 18 and 24 months), with each patient’s
baseline value used as a covariate in the analysis.
Additional analyses were conducted to determine whether
age, disease severity, treatment with ERT and/or genotype
were associated with cognitive performance. In previous
work, various cut off values on the SSI have been used to
separate mild disease from severe disease. Mild disease has
been defined by a SSI of ≤ 5, and severe disease by a score
of ≥ 15 (Shitrit et al 2003), but a cut off value of 11 has also
been used (Aker et al 1993). Consequently, subgroup anal-
ysis for both cut off values was undertaken. The following
genotype subgroups were analysed: patients who were ho-
mozygous for N370S, patients who had at least one N370S
allele, and patients who had at least one L444P mutation.
Differences were tested with the Student’s t-test or Mann
Whitney test, and Pearson’s correlation was used to assess
correlations between variables.
As indicated before, the prevalence and incidence of
polyneuropathy were investigated in the same study group.
To assess whether the peripheral and central nervous system
symptoms were related, multivariate analyses were per-
formed using ANCOVA, fitting age as a covariate and
disease severity and polyneuropathy as factors. Subsequently,
ANCOVA was used correcting for baseline values to assess
whether impairments changed differentially over time in the
disease severity and polyneuropathy subgroups.
Data were collected by Actelion Pharmaceuticals Ltd,
sponsor of the study. Statistical analyses were performed
by co-author KAW, practice leader of United BioSource
Corporation.
Results
Patients
From a total of 104 patients screened for inclusion in the
original cohort, 102 patients attended at least one post
Table 1 CDR composite scores
Composite score Measures contributing Aspects of cognitive function involved
Power of attention Simple reaction time Ability to focus attention and ignore
distraction. A measure of early
information processing.
Choice reaction time
Digit vigilance speed of detections
Continuity of attention Choice reaction time accuracy (%) Ability to sustain attention
(concentration, vigilance)Digit vigilance task detections (%)
Digit vigilance task – false alarms
Quality of working memory Numeric working memory & spatial
working memory sensitivity scores
Ability to successfully hold information
temporarily in both articulatory working
memory and spatial working memory.
Short-term memory.
Quality of episodic memory Percentage overall accuracy on word
and picture recognition tasks
Ability to encode, store and subsequently
successfully retrieve verbal and non-verbal
information. Long-term memory.
Speed of memory Speeds of correct identifications in
working memory, word recognition
and picture recognition tasks
A measure of the time taken to process verbal
and non-verbal information and to successfully
retrieve the information from both working
memory and episodic memory
Variability of attention The coefficients of variance for simple
reaction time, choice reaction time
and digit vigilance speed of detections
A measure that reflects fluctuations in attention
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baseline visit. One patient withdrew after screening due to an
inability to commit to follow-up assessments, and one patient
requested withdrawal after the first visit as she moved to
another country. Of these 102 patients, 18 patients were ex-
cluded from the analyses for this study due to the use of
sedative drugs (including opioid analgesics), concomitant
neurological or psychiatric disorders, mutations associated
with neuronopathic Gaucher disease or unknown mutations.
Of the remaining 84 patients, 78 completed the two years
study. Four patients were withdrawn due to starting treat-
ment with miglustat, one patient was non-compliant and one
patient requested withdrawal from study for personal rea-
sons. Patient characteristics are summarised in Table 2.
Cognitive function tests
Taking all baseline results, patients with GD1 were mildly
impaired relative to age-matched subjects on the composite
scores power of attention and speed of memory (Fig. 1). For
the whole population, power of attention showed a mean ±
SD Z-score of -0.9±1.37 and speed of memory showed a
mean ± SD Z-score of -1.39±1.49. The results were nor-
mally distributed which implies that the mean Z-scores were
not due to a few outliers but rather reflecting mild deficits in
the whole cohort. For power of attention 36 patients had
deficits of 1 SD or greater and 16 had deficits of 1.96 or
greater. For speed of memory 47 patients had deficits of 1
SD or greater and 24 had deficits of 1.96 or greater.
Since the GD1 patients showed decreased speed meas-
ures but scored the same or even slightly better in the
accuracy scores compared to the normative population, an
additional ANCOVA analysis was conducted on the speed
measures, fitting the accuracy scores as covariates. This
analysis showed that the deficits in power of attention and
speed of memory were independent from the accuracy
scores, indicating that the slowed speed scores reflected
cognitive deficits and not differences in response strategy.
Post baseline measurements
Power of attention showed a significant decline in perfor-
mance of around -0.3 at each of the post baseline visits (p<
Table 2 Patient characteristics
All patients (N084)
Demographics
Gender, male / female, n (%) 41 (49) / 43 (51)
Age in years, median (range) 40 (18-75)
Age-bands, years
18-32, n 23
33-41, n 23
42-52, n 19
53-75, n 19
Country of origin
Netherlands 21 (25%)
Germany 19 (23%)
Hungary 18 (21%)
Spain 6 (7%)
United Kingdom 3 (4%)
Croatia 4 (5%)
Serbia 13 (15%)
GD1 characteristics
Genotype, n (%)
N370S/N370S 11 (13.1%)
N370S/L444P 18 (21.4%)
N370S/84GG 2 (2.4%)
N370S/IVS2+1 1 (1.2%)
N370S/other 39 (46.4%)
N370S/unknown 8 (9.5%)
L444P/G377S 1 (1.2%)
RECNCI1/D140H 1 (1.2%)
R463C/R463C 1 (1.2%)
A446P/A446P 1 (1.2%)
R48Q/T323I 1 (1.2%)
Time from diagnosis in years, median (range) 15 (0-56)
Splenectomised, n (%) 26 (31)
SSI, median (range) 8 (2-21)
Plasma chitotriosidase‡ in nmol/ml.hour,
median (range)
5,332 (100-49,860)
ERT
Receiving ERT, n (%) 71 (84.5)
Duration in years, median (range) 2.1 (0.1-13.6)
Dosage in IU / kg / month, median (range) 54 (12-137)
‡ data available from 82 patients (normal range, 4–120 nmol/ml.hour);
ERT, enzyme replacement therapy.
Fig. 1 Z-scores at baseline by age quartiles, means with 95% confidence
intervals
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0.02), but no main effect of time-point was seen (F(3,83)0
0.63, p00.6), indicating that patients declined from base-
line, but that there was no progressive decline thereafter. For
continuity of attention, the data showed stable performance
over time. Improvements in performance on quality of epi-
sodic memory from baseline to each of the subsequent
assessments were found (p<0.002), but there was no signifi-
cant main effect of time point (F(3,82)00.84, p00.8). Perfor-
mance on the speed of memory tasks was better at each of the
post baseline time-points (p<0.001), and amain effect of time-
point was found (F(3,82)03.04, p00.03). The data of Quality
of Working Memory and Variability of Attention showed
fluctuations in performance over the duration of the study.
Relation between cognitive function and age, disease
severity, ERT, genotype and polyneuropathy
Pearson’s correlation showed correlations between age and
variability of attention (rp0-0.312, p<0.005) and between
age and quality of working memory (rp0-0.232, p<0.05):
older patients scored worse on these scores than younger
patients did. Besides, the SSI correlated with power of
attention (rp0-0.265, p<0.02).
Cognitive function did not differ between ERT treated
and untreated patients. Analyses by genotype revealed that
patients carrying at least one N370S mutation (n079) did
not differ to those without such a mutation (n05). Likewise,
cognitive performance of N370S homozygotes and L444P
heterozygotes did not differ from the results in patients with
other genotypes.
Of the 84 patients included in the analyses, 14 (16.7%)
were diagnosed with sensory motor axonal polyneuropathy
(Biegstraaten et al 2010). Polyneuropathy patients were
older than patients without polyneuropathy (60 versus
37 years, p<0.001). The median SSI did not differ between
patients with polyneuropathy and patients without polyneur-
opathy (8.5 versus 7, p00.154). There was no correlation
between age and the SSI (rp00.137, p00.219), nor did age
differ between the disease severity groups. To evaluate the
relationship of disease severity (using both criteria as dis-
cussed above) and polyneuropathy to the baseline scores of
the patients, factorial ANCOVAs were performed, fitting the
presence of polyneuropathy and the disease severity as
factors, and age as a covariate. No effects of polyneuropathy
were identified for power of attention, but severely affected
patients (SSI ≥ 15) scored worse compared to mildly affected
patients (SSI ≤ 5) on this composite measure (-1.93 versus -
0.47, 95%CI -0.21, -2.72, p<0.025). No differences were
found if a cut-off value of 11 was used. There was no inter-
action between polyneuropathy and disease severity. No dif-
ferences were found for the other measures. The cognitive
profile did not change differentially over time in the disease
severity and polyneuropathy subgroups.
Discussion
This study on cognitive function in GD1 patients revealed
mild deficits for power of attention and speed of memory in
this patient group, reflecting a poorer ability to focus attention
and a slowed retrieval of information held in memory in
comparison to age-matched healthy controls. Unfortunately,
subjective cognitive complaints were not assessed in this
study. However, experience shows us that GD1 patients usu-
ally do not report difficulties in conducting daily activities or
cognitive problems (personal communications). This suggests
that the deficits in our patients were subtle and of doubtful
clinical relevance. Although there was no necessity for poly-
neuropathy and cognitive dysfunction to coincide we decided
to assess whether the neurological symptoms were related.
The analyses revealed that these symptoms were unrelated,
suggesting different underlying pathological mechanisms.
The cognitive profile of GD1 patients shows some similar-
ities with the profile of type 3 patients: a study in GD3
children has shown that the cognitive deficits in these patients
typically affect general nonverbal skills with a relative preser-
vation of verbal skills. About 60% had below-average intel-
lectual skills, and the weaknesses were specifically observed
in the areas of processing speed, visual-spatial relationships,
and perceptual organization skills (Goker-Alpan et al 2008).
Thus, GD1 as well as GD3 patients exhibit decreased speed
measures. However, type 3 patients have a broader spectrum
of cognitive function deficits. Moreover, GD3 patients en-
counter problems in conducting their daily activities, while
patients with GD1 do not. It is still unclear why some patients
develop type 1 disease and others type 3 disease, despite the
same underlying defective gene, and in some instances even
the same underlying genotype.
It has been hypothesised that a toxic metabolite is respon-
sible for the nervous system damage in type 2 and 3 patients;
glucosylsphingosine, a glycosphingolipid that is also degrad-
ed by glucocerebrosidase, is a highly cytotoxic compound that
has been demonstrated to be elevated in spleen and liver
samples of Gaucher patients of all types, while levels in brain
samples were elevated only in those with neuronopathic forms
(Orvisky et al 2002). However, it is still unclear why these
levels are only elevated in neuronopathic Gaucher disease
patients. Moreover, this does not explain the mild cognitive
deficits in type 1 patients as found in the present study.
A second hypothesis is that the (minimal) amount of
accumulated glucosylceramide in the central nervous system
plays a role. Increased intracerebral glucosylceramide levels
have been found in Gaucher patients; a study in post-
mortem human brain tissue revealed glucosylceramide
levels ranging between 0.7 and 2.9 nnmol/mg in control
brains, between 6.1 and 13.9 in type 1 Gaucher disease
patients, between 7.8 and 15.3 in type 3 patients, and
between 27.9 and 36.3 in type 2 patients (Pelled et al
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2005). Neuropathologically, the hippocampal CA2-4 areas
are the most consistent and characteristic regions of pathology
in Gaucher disease (Wong et al 2004). This may be - partly -
explained by the massive association network of these brain
regions which results in a hyperexcitable state; in healthy
individuals the hyperexcitable state is moderated by strong
inhibitory influences, although subtle alterations of the CA2-
4 neurons can result in pathologic hyperexcitability states
(Wong et al 2004). Elevated glucosylceramide levels in these
neurons may be such an alteration; indeed, increased gluco-
sylceramide levels have been shown to induce an elevated
intracellular calcium release in the CA2-4 neurons (Lloyd-
Evans et al 2003;Korkotian et al 1999), with a significant
correlation between levels of glucosylceramide and the amount
of calcium release (Pelled et al 2005). Therefore, elevated
intracerebral glucosylceramide levels may lead to damage to
these hippocampal sub regions in patients with type 3, but also
in patients with type 1Gaucher disease, albeit to a lesser extent.
A previous study on cognitive performance in GD1
patients did not demonstrate a change in cognitive function,
although slight visuo-spatial disturbances were observed
(Elstein et al 2005). In our study visuo-spatial skills were
not tested as such. Visuo-spatial disturbances may precede
or be part of cortical and subcortical dementia syndromes.
The decreased speed measures as found in our study suggest
subcortical involvement rather than cortical degeneration.
Indeed, diffusion tensor imaging (DTI, a tool used to inves-
tigate white matter structure) in three paediatric type 1
patients showed scattered white matter changes, although
these abnormalities were largely non-specific (Davies et al
2011). Furthermore, the previously mentioned neuropathol-
ogy study revealed white matter gliosis in all seven adult
GD1 patients studied (Wong et al 2004).
Another interesting observation is the correlation be-
tween age and variability of attention. Although the vari-
ability of attention measure was not initially planned to be
included in the analysis, it has been demonstrated to be an
aspect of cognitive function specifically impaired in Demen-
tia with Lewy Bodies (DLB) and PD dementia (PDD) when
compared to patients with Alzheimer’s disease, PD or con-
trols (Walker et al 2000; Ballard et al 2010), and was thus
considered of potential interest. The hippocampal CA2-4
regions affected in type 1 as well as type 3 patients (Wong
et al 2004) correspond with the neuropathological abnor-
malities seen in DLB which is one of the few disorders that
selectively target the hippocampal CA2-3 regions. Moreover,
among the Gaucher brains that were neuropathologically in-
vestigated, four patients had concomitant type 1 Gaucher
disease and PDD or DLB. They all had synuclein-positive
inclusions similar to the Lewy bodies seen in PD and DLB.
Taking these findings together, it seems that DLB and GD1
patients have some neuropathological and cognitive features
in common, albeit that the overall cognitive profile of GD1
patients is much less severe and without clinical consequence
in comparison with the profile of DLB patients. These simi-
larities are of particular interest since the two diseases have
been associated with each other. One study showed that 8 out
of 35 subjects with a pathological diagnosis of DLB had a
mutation in the GBA gene (Goker-Alpan et al 2006).
The pathophysiological relationship between GBA and
DLB has not yet been completely elucidated. It has been
suggested that a (relatively) diminished enzymatic activity
in Gaucher patients as well as carriers leads to an increase of
glucocerebrosides in specific brain regions which can then
result in neuronal dysfunction. Alternatively, mutated glu-
cocerebrosidase (present in patients as well as carriers)
might enhance aberrant fibrillization of α-synuclein and
aggregation of this protein, a process that is necessary for
the formation of Lewy bodies (Lwin et al 2004).
With respect to study limitations, our findings are based on
a computerised system, and not on a traditional psychologist-
administered neuropsychological test battery. However, the
CDR system has been proven to be a valid measure of cogni-
tive function (Simpson et al 1991). Moreover, advantages of
the CDR system are the objective nature of the tests, which
can be administered in multiple languages and the short time
needed to complete the test battery (30 minutes). The age-
matched normative sample is large which makes comparisons
between diseased and healthy people valuable. In contrast to
these healthy controls, however, GD1 patients underwent the
cognitive assessment among other investigations which might
have led to an underestimation of their cognitive capacities
due to fatigue or situational anxiety. However, the above
average performance on the composite scores continuity of
attention, quality of working memory and quality of episodic
memory makes it unlikely that these factors played a major
role in the findings of the present study. Besides, our patients
were compared to healthy controls. We do not know to what
extent the impaired speed measures found in the present study
are due to suffering from a chronic disease in general rather
than GD1 itself. However, patients with for instance rheuma-
toid arthritis showed a normal cognitive profile, making it
unlikely that having a chronic disease is the main cause of
our findings (Park et al 1999). The absence of a main effect
of time-point in this study is probably due to the relatively short
follow-up time. The decline in power of attention from baseline
without progressive decline thereafter may have been due to the
absence of training sessions prior to the follow-up visits. The
pattern of improvement of quality of episodic memory and
speed of memory may have reflected a training effect with
repeated assessments. However, such effects have not been
seen in other studies with healthy controls (Wesnes et al 2000).
Despite these shortcomings, we feel confident that findings
from this study are robust since GD1 patients with concomitant
diseases that could distort our results were all excluded. We
therefore propose that our observations are due to GD1 itself.
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Conclusion
GD1 patients develop impaired cognitive speed measures,
although the impact on everyday life was not assessed.
Further studies are needed to establish whether these abnor-
malities are related to Gaucher disease itself.
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